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Blood pressureChronic exposure to low lead concentration produces hypertension; however, the underlying mechanisms
remain unclear. We analyzed the role of oxidative stress, cyclooxygenase-2-dependent pathways and MAPK in
the vascular alterations induced by chronic lead exposure. Aortas from lead-treated Wistar rats (1st dose:
10 μg/100 g; subsequent doses: 0.125 μg/100 g, intramuscular, 30 days) and cultured aortic vascular smoothmus-
cle cells (VSMCs) fromSpragueDawley rats stimulatedwith lead (20 μg/dL)were used. Lead blood levels of treat-
ed rats attained 21.7 ± 2.38 μg/dL. Lead exposure increased systolic blood pressure and aortic ring contractile
response to phenylephrine, reduced acetylcholine-induced relaxation and did not affect sodium nitroprusside
relaxation. Endothelium removal and L-NAME left-shifted the response to phenylephrine more in untreated
than in lead-treated rats. Apocynin and indomethacin decreased more the response to phenylephrine in treated
than in untreated rats. Aortic protein expression of gp91(phox), Cu/Zn-SOD, Mn-SOD and COX-2 increased after
lead exposure. In cultured VSMCs lead 1) increased superoxide anion production, NADPH oxidase activity and
gene and/or protein levels of NOX-1, NOX-4, Mn-SOD, EC-SOD and COX-2 and 2) activated ERK1/2 and p38
MAPK. Both antioxidants and COX-2 inhibitors normalized superoxide anion production, NADPH oxidase activity
and mRNA levels of NOX-1, NOX-4 and COX-2. Blockade of the ERK1/2 and p38 signaling pathways abolished
lead-induced NOX-1, NOX-4 and COX-2 expression. Results show that lead activation of the MAPK signaling
pathways activates inﬂammatory proteins such as NADPH oxidase and COX-2, suggesting a reciprocal interplay
and contribution to vascular dysfunction as an underlying mechanisms for lead-induced hypertension.
© 2015 Elsevier Inc. All rights reserved.Introduction
Lead is an environmental pollutant that has emerged as a potential
risk factor related to the development of cardiovascular complications.
It has been extensively reported that chronic exposure to low levels of
lead causes hypertension (Gonick et al., 1997; Vaziri et al., 1997;clooxygenase;MAPK,mitogen-
tracellular signal-regulated pro-
Ciências Fisiológicas, Centro de
29040-095 Vitória, ES, Brazil.
e Farmacología, Universidad
d, Spain.
ercedes.salaices@uam.esVaziri et al., 1999). Several mechanisms have been implicated in lead-
induced hypertension. Thus, alterations of themuscular and endothelial
layers of blood vessels induced by direct interaction with lead cause
disturbances in the renin–angiotensin–aldosterone system, stimulation
of the sympathetic systemand an excessive synthesis of reactive oxygen
species (ROS) (Zawadzki et al., 2006). Moreover, alterations in calcium
exchangeability (Goldstein, 1993), inhibition of the Na+/K+-ATPase
(Weiler et al., 1990), direct activation of smooth muscle protein kinase
C (Watts et al., 1995) and endothelial dysfunction (Silveira et al.,
2014) have also been reported.
It has been demonstrated that alterations in vascular tone are possi-
bly involved in lead-induced hypertension (Marques et al., 2001). ROS
have a key role in the pathogenesis of cardiovascular disease, which
results in the disturbance of the structure of biological cell membranes
inmany organswithin an organism, the impairment of cellular function,
alterations of NO synthase activity and increased concentrations of
128 M.R. Simões et al. / Toxicology and Applied Pharmacology 283 (2015) 127–138inﬂammatorymarkers (Cai and Harrison, 2000; Elahi et al., 2009). COX-
2, a pro-inﬂammatory enzyme, has been described as a source of free
radicals (Virdis et al., 2013; Martínez-Revelles et al., 2013). It has been
established that COX-2-derived prostanoids contribute to the endothe-
lial dysfunction in hypertensive animals (Wong et al., 2010). A recent
study by our groupdemonstrated that low levels of blood lead increased
vascular reactivity. This increase was associated with reduced NO bio-
availability, increased ROS, increased participation of COX-2-derivated
prostanoids and increased renin–angiotensin system activity (Silveira
et al., 2014).
Mitogen-activated protein kinases (MAPKs) are a family of enzymes
that comprise global groups of signaling proteins that play critical regu-
latory roles in cell physiology (Chang and Karin, 2001; Chen et al.,
2001). The activation of extracellular signal-regulated protein kinases
(ERK1/2) is mainly associated with cell survival and proliferation
(Hetman and Gozdz, 2004), while c-Jun N-terminal kinases (JNKs)
and p38 MAPK cascades are associated with the promotion of inﬂam-
mation and programmed cell death (Tibbles and Woodgett, 1999;
Chen et al., 2001). Some studies have linked the prostanoid pathway
to the activation of the MAPK signaling cascade and to the induction
of oxidative stress (Chen et al., 2005; Kim et al., 2005). In addition,
MAPK activation by heavy metals may modulate mechanisms that
induce oxidative stress (Leonard et al., 2004). Despite the extensive
documentation of the toxic effects of lead in the cardiovascular system,
a complete and detailed elucidation of the cell target and mechanisms
by which lead exerts its effects remains to be deﬁned. This study in-
vestigates the role of oxidative stress and cyclooxygenase-2 in the
altered vascular reactivity induced by a 30-day treatment with a lowFig. 1. Chronic lead treatment affects aortic reactivity. Effects of 30-day exposure to lead on th
nitroprusside (SNP) in aortic rings. Data are expressed as themean±SEM. *Pb 0.05 versus untre
in parentheses.concentration of lead. In addition, we analyze the ability of lead to acti-
vate ERK1/2, p38MAPK and JNK in VSMCs and its implication on the ox-
idative stress and cyclooxygenase-2 pathways involved in vascular
alterations induced by lead.
Materials and methods
Ethics statement and animals. Male Wistar (250–300 g) and Sprague
Dawley (SD) (4 months old) rats were used. All experimental proce-
dures were approved by the Institutional Ethics Committee of the
Federal University of Espirito Santo (CEUA-UFES 063/2011) and by the
Ethical Committee of Research of the Universidad Autónoma de
Madrid, Spain (CEI-UAM 31–759). This study was carried out in strict
accordance with the guidelines for biomedical research as stated by
the Brazilian Societies of Experimental Biology, the Guide for the Care
and Use of Laboratory Animals published by the US National Institute of
Health (NIH publication No. 85-23, revised 1996) and with the current
Spanish and European laws (RD 223/88Ministerio de Administraciones
Públicas, MAPA, and 609/86).
Rats were housed under a 12-h light/12-h dark cycle, had free access
to water and were fed with rat chow ad libitum. In one set of experi-
ments, Wistar rats were divided into two groups: control (vehicle-
saline, intramuscular) or treated with lead acetate for 30 days (1st
dose: 10 μg/100 g; subsequent doses: 0.125 μg/100 g, intramuscular,
to cover daily loss). At the end of the treatment, rats were anesthetized
and killed by exsanguination. The thoracic aortaswere carefully dissect-
ed out, and the fat and connective tissue removed. For the vascular reac-
tivity experiments, the aortas were divided into cylindrical segmentse concentration–response curves to (A) phenylephrine, (B) acetylcholine and (C) sodium
atedusing two-wayANOVA and Bonferroni post-test. Number of animals used is indicated
Table 1
pD2 and the maximum response to phenylephrine in aortic segments from untreated
rats and rats treated with lead with or without endothelium (E-), L-NAME, apocynin, or
indomethacin.
Untreated Lead treated
Rmax pD2 Rmax pD2
Control 99 ± 3.5 6.37 ± 0.20 127 ± 5.2⁎ 7.26 ± 0.22⁎
E− 137 ± 9.6⁎ 7.11 ± 0.07⁎ 148 ± 7.9† 7.87 ± 0.30†
L-NAME 133 ± 8.2⁎ 6.95 ± 0.12 146 ± 2.9† 7.91 ± 0.16†
Apocynin 84 ± 5.5⁎ 6.22 ± 0.18 89 ± 6.7† 7.39 ± 0.25
Indomethacin 89 ± 3.4 6.73 ± 0.28 90 ± 4.5† 7.65 ± 0.25
Data are expressed as themean± SEM. Rmax valueswere expressed as a percentage of the
maximal response induced by 75 mM KCl. Rmax: Maximal response.
⁎ P b 0.05 vs Control untreated.
† P b 0.05 vs Control lead treated.
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rats were isolated and processed to obtain primary cultures of vascular
smooth muscle cells (VSMCs) for cell culture experiments.
Blood pressure measurements. Indirect systolic blood pressure wasmea-
sured at the beginning and at the end of treatment using tail-cuff pleth-
ysmography (IITC Life Science, Inc.). Conscious rats were restrained for
5–10 min in a warm and quiet room and conditioned to numerous
cuff inﬂation–deﬂation cycles by a trained operator. Systolic blood pres-
sure was measured, and the mean of ten measurements was recorded.
Blood lead level measurements. Blood lead levels were measured by
inductively coupled plasma mass spectrometry (NexIon 300D,
PerkinElmer, USA) after acid decomposition of thewhole blood samples
as previously described (Liu et al., 1996). The samplesweremeasured in
triplicate.
Vascular function. Vascular function was studied in aortic segments by
isometric tension recording using an isometric force transducer (TSDFig. 2. Effects of chronic lead treatment on NO-mediated vascular response in aortic rings. Eff
response curve to phenylephrine in aortic rings from untreated and treated rats. *P b 0.05 v
differences in the area under the concentration–response curves (dAUC) in (A) endothelium-
versus untreated by Student's t-test. Data are expressed as the mean ± SEM. Number of anima125C, CA, USA) connected to an acquisition system (Biopac Systems,
Inc., Santa Barbara, USA). Segments were mounted between two paral-
lel wires in organ baths containing Krebs–Henseleit solution (KHS, in
mM: 124 NaCl, 4.6 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 0.01 EDTA,
23 NaHCO3, 11.1 glucose) at 37 °C and gassed with 95% O2–5% CO2
(pH 7.4). After a 45-min equilibration period, aortic rings were initially
exposed twice to 75 mMKCl to test their functional integrity and to as-
sess the maximal developed tension. The presence of endothelium was
conﬁrmed by the effect of 10 μM acetylcholine in segments previously
contracted with 1 μM phenylephrine. A relaxation equal to or greater
than 90% was considered demonstrative of the functional integrity of
the endothelium. After a washout period, single concentration–
response curves to phenylephrine (0.1 nM–0.3 mM) or acetylcholine
(ACh, 0.01 nM–0.3 mM) were performed. In some experiments, con-
centration–response curves to sodium nitroprusside (SNP, 0.01 nM–
0.3 mM) were performed in segments contracted with phenylephrine
(1 μM).
Parallel experiments with aortic segments from the same animal
were performed in the absence (control) and presence of the nonspecif-
ic NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 100 μM),
the cyclooxygenase inhibitor indomethacin (10 μM) and the NADPH
oxidase inhibitor apocynin (30 μM). These drugs were added to the
bath 30 min before the phenylephrine curves. The inﬂuence of the
endothelium on the response to phenylephrine was investigated after
mechanical removal of this vascular component by rubbing the lumen
with a needle. The absence of endothelium was conﬁrmed by the in-
ability of 10 μM acetylcholine to produce relaxation.In situ detection of vascular O2
•− production. The oxidative ﬂuorescent
dye dihydroethidium (DHE) was used to evaluate O2•− production in
situ, as previously described (Wiggers et al., 2008). Hydroethidine freely
permeates the cell membrane and is oxidized in the presence of O2•− to
ethidium bromide, which is trapped by intercalation with DNA.
Ethidium bromide is excited at 546 nm and has an emission spectrumects of (A) endothelium removal (E−) and (B) L-NAME (100 μM) on the concentration–
ersus E+ or control using two-way ANOVA and Bonferroni post-test. The inset shows
denuded and intact segments and (B) in the presence and absence of L-NAME. *P b 0.05
ls used is indicated in parentheses.
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and placed on a glass slide. Serial sectionswere equilibrated under iden-
tical conditions for 30 min at 37 °C in Krebs–HEPES buffer (in mM: 130
NaCl, 5.6 KCl, 2 CaCl2, 0.24 MgCl2, 8.3 HEPES, and 11.1 glucose, pH =
7.4). Fresh buffer containing DHE (2 μM) was applied topically to each
tissue section, covered with a cover slip, incubated for 30 min in a
light-protected humidiﬁed chamber at 37 °C and then viewed with an
inverted ﬂuorescence microscope (NIKON Eclipse Ti-S, ×40 objective;
N.Y., U.S.A.) using the same imaging settings in the untreated and
lead-treated rats. Fluorescence was detected with a 568-nm long-pass
ﬁlter. For quantiﬁcation, eight frozen tissue segments per animal were
sampled for each experimental condition and averaged. Themean ﬂuo-
rescence densities in the target region were calculated.
Cell culture. Primary cultures of VSMCs were obtained from SD rats as
previously described (Aguado et al., 2013). Rat thoracic aortas wereFig. 3. Lead induces vascular oxidative stress. (A) Representative ﬂuorescent photomicrographs
anion quantiﬁcation. *P b 0.05 versus untreated by Student's t-test. (B) Effects of the NADPH ox
rings from untreated and treated rats; inset shows the difference in the area under the concent
way ANOVA and Bonferroni post-test or versus untreated by Student's t-test. (C) Densitometri
aortas from untreated and treated rats. Representative blots are also shown. Data are expressed
is indicated in parentheses.aseptically removed, cleaned of fat tissue and blood cells and placed
in cold (4 °C) Dulbecco's Modiﬁed Eagle's Medium (DMEM)/F-12
(HAM) medium (Sigma Chemical Co., St. Louis, MO, USA) containing
0.1% BSA, 200 U/mL penicillin, and 200 μg/mL streptomycin (Gibco,
Invitrogen, Paisley, UK). The aortas were digested in the same medium
containing 2 mg/ml collagenase type II (Worthington Biochemical Cor-
poration, Lakewood, New Jersey, USA) and incubated for 30min at 37 °C
in a humidiﬁed atmosphere of CO2 (5%). Then, after peeling off the ad-
ventitia using forceps, the medial smooth muscle layer was cut into
small pieces and placed on 60 × 15-mm tissue dishes in DMEM/F-12
(HAM) medium supplemented with 10% fetal calf serum (Biological In-
dustries, Kibbutz, Israel) containing 100 U/mL penicillin and 100 μg/mL
streptomycin. Cells were allowed to reach conﬂuence (10–12 days).
Conﬂuent cells were trypsinized with PBS/trypsin-EDTA (Sigma),
washed and plated at a density of 30% in DMEM medium. Cells were
identiﬁed as smooth cells by immunocytochemical staining withof arterial sections labeled with the oxidative dye hydroethidine and vascular superoxide
idase inhibitor apocynin on the concentration–response curve to phenylephrine in aortic
ration–response curve (dAUC) of the respective group. *P b 0.05 versus control using two-
c analysis of western blots for gp91(phox), Cu-Zn/SOD and Mn/SOD protein expression in
as themean± SEM. *P b 0.05 versus untreated by Student's t-test. Number of animals used
131M.R. Simões et al. / Toxicology and Applied Pharmacology 283 (2015) 127–138speciﬁc monoclonal anti-α-actin antibody (Sigma Chemical Co).
We should emphasize that the cells employed here were the product
of primary culture of VSMCs studied after only 5 passages to avoid
transformation.
VSMCs were plated onto 6-well plates and cultured until 80% con-
ﬂuence. DMEM/F-12 (HAM) medium supplemented with serum was
replaced with fresh medium containing 100 U/mL penicillin and
100 μg/mL of streptomycin for 24 h before treatment. For the experi-
ments, quiescent cells were incubated with vehicle (control) or with
lead acetate (20 μg/dL, during 48 h) in the absence or presence
(30 min before and throughout lead incubation) of the ROS scavenger
tempol (10 μM), the NOX-1 inhibitorML 171 (0.5 μM), the speciﬁc scav-
enger of mitochondrial superoxide mito-TEMPO (5 μM) or the COX-2
inhibitors celecoxib (10 μM) and rofecoxib (10 μM). In another set of ex-
periments, cells were incubated with lead acetate for different stimula-
tion times (5 min–24 h) to evaluate the effect on the activation of p38,
ERK1/2, JNKs MAPK and Akt. Finally, the effects of the ERK1/2 inhibitor
U0126 (10 μM) and the p38MAPK inhibitor SB203580 (10 μM) on COX-
2, NOX-1 and NOX-4 mRNA levels were evaluated in cells exposed to
20 μg/dL lead acetate for 48 h.Cell viability assay. We used theMTT reduction assay following the pro-
cedure previously described (Mosmann, 1983). In brief, after incubation
with lead acetate at different concentrations, 0.5 mg/mL MTT (3-(4, 5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) was added to
each well, and incubation was performed at 37 °C for 2 h. The formazan
salt formedwasdissolved inDMSO, and colorimetric determinationwas
performed at 540 nm. Control cells without lead were considered toFig. 4. Role of prostanoids in aortic segments from untreated and treated rats. (A) Effect of
phenylephrine in aortic rings from untreated and treated rats. *P b 0.05 versus control using t
COX-2 protein expression in aortas from untreated and treated rats. Representative blots ar
mean ± SEM. Number of animals used is indicated in parentheses.have 100% viability. VCMS viability after exposure to leadwas expressed
as the percent of control within each individual experiment.
Detection of superoxide anion production by ﬂuorescencemicroscopy. VSMCs
were incubated with lead for 48 h, and intracellular O2•− production
was measured by ﬂuorescence imaging analysis using DHE as de-
scribed above. Brieﬂy, VSMCs were plated onto glass coverslips
inserted into 6-well plates and cultured and preincubated with
tempol (10 μM) and mito-TEMPO (5 μM) 30 min before lead expo-
sure. Afterwards, cells were loaded with DHE (10 μM) in cell culture
medium (DMEM/F-12 HAM, serum free) for 30 min at 37 °C. Images
were then acquired with a Leica TCS SP2 confocal system (×40) and
processed using Metamorph image analysis software. Non-
stimulated VSMCs were imaged daily in parallel using the same
image settings during the course of the study. DHE ﬂuorescence
was quantiﬁed in individual cell nuclei (10–20 nuclei/image/experi-
mental condition). At least 5 independent experiments were per-
formed. Then, we expressed the effects of the different drugs as
fold increases over the control.
NADPH oxidase activity. Cells were grown on 6-well culture plates and
incubated with lead (20 μg/dL, during 48 h). The O2•− production ge-
nerated by NADPH oxidase activity was determined by a chemilu-
minescence assay using lucigenin (5 μM) and NADPH (100 μM). The
reaction was started by the addition of a mixture of lucigenin and
NADPH to the protein sample in a ﬁnal volume of 250 μL. Chemilumi-
nescence was determined every 2.4 s for 5 min in a plate luminometer
(AUTO-Lumat LB953, Berthold Technologies GmbH & Co. KG, Badthe nonselective COX inhibitor indomethacin on the concentration–response curve to
wo-way ANOVA and Bonferroni post-test. (B) Densitometric analysis of western blots for
e also shown. *P b 0.05 versus untreated by Student's t-test. Data are expressed as the
132 M.R. Simões et al. / Toxicology and Applied Pharmacology 283 (2015) 127–138Wildbad, Germany). Buffer blankwas subtracted from each reading. Lu-
minescence was normalized by protein concentration measured by the
Lowry assay and data were expressed as fold increase over the control.Western blot analysis. Proteins from homogenized aortas and cells were
separated on a 10% SDS-polyacrylamide gel and electrophoretically
transferred to polyvinylidene diﬂuoride membranes (Amersham, GE
Healthcare, Buckinghamshire, UK) that were incubated overnight at
4 °C with monoclonal antibodies for COX-2 (1:200; Cayman Chemi-
cal, Ann Arbor, MI, USA), COX-1 (1:500, Cayman Chemical), and
gp91(phox) (1:1000, Transduction Laboratories, Lexington, UK)
and polyclonal antibodies for Mn-SOD (0.025 μg/mL; StressGen
Bioreagents Corp., Victoria, Canada), Cu/Zn-SOD (1:10000; Nventa
Biopharmaceuticals, Victoria, BC, Canada), EC-SOD (1:4000; Enzo
Life Sciences), phospho ERK1/2 and ERK1/2, phospho p38 and p38Fig. 5. Lead induces oxidative stress in vascular smoothmuscle cells. Effect of lead (Pb) on VSM
Tempol (10 μM) (A); NADPHOxidase activity in the absence or the presence ofML 171 (0.5 μM
expression in the absence or the presence of Celecoxib and Rofecoxib (C,D); Mn-SOD, Cu/
with dihydroethidium and representative blots are also shown. Data are expressed as the me
one-way ANOVA followed by Tukey test or Student's t-test. Number of different cultures is indMAPK, phospho JNK and JNK, phospho Akt and Akt (1:1000; Cell Sig-
naling, Boston, MA). Membranes were thoroughly washed and incu-
bated with horseradish peroxidase-coupled anti-rabbit (1:2000;
Bio-Rad, USA) or anti-mouse (1:5000; StressGen Bioreagents Corp.,
Victoria, Canada) antibodies for 1 h at room temperature. After thor-
ough washing, the bands were detected using an ECL plus Western
Blotting detection system (GE Healthcare) after exposure to X-Ray
AX ﬁlm (Konica Minolta, Tokyo, Japan and Hyperﬁlm ECL Interna-
tional). Signals on the immunoblot were quantiﬁed using the
Image J computer program.α-Actin (aorta) (1:5000, Sigma Chemical
Co) and β-actin (cells) (1:10,000; Transduction Laboratories) ex-
pressions were used as loading controls.Quantitative real time PCR assay. Total RNA was obtained using TRI
Reagent (Sigma Chemical Co.) according to the manufacturer'sC superoxide anion production in the absence or the presence of mito-TEMPO (5 μM) and
), Tempol (10 μM), Celecoxib (10 μM) and Rofecoxib (10 μM) (B); NOX-1 and NOX-4 gene
Zn-SOD and EC-SOD protein expression (E–G). Representative images of cells stained
an ± SEM. *P b 0.05 versus untreated cells (Ct or untreated), &P b 0.05 versus Pb using
icated in parentheses.
133M.R. Simões et al. / Toxicology and Applied Pharmacology 283 (2015) 127–138recommendations andwas reverse transcribed using a High Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) with
random hexamers. qRT-PCR for COX-2, NOX-1 and NOX-4 was per-
formed using the ﬂuorescent dye SyBRGreen (iTaq FAST SyBRGreen
Supermix with ROX, Bio-Rad, USA). To normalize, we ampliﬁed β2-
microglobulin as a housekeeping gene. All qRT-PCRs were performed
in duplicate. Primers sequences were as follows: COX-2 (FW: AAGG
GAGTCTGGAACATTGTGAAC; RV: CAAATGTGATCTGGACGTCAACA),
NOX-1 (FW: CGGCAGAAGGTCGTGATTA; RV: TGGAGCAGAGGTCA
GAGT), NOX-4 (FW: GCCTCCATCAAGCCAAGA; RV: CCAGTCATCCAG
TAGAGTGTT) and β2-microglobulin (FW: ACCCTGGTCTTTCTGGTG
CTT; RV: TAGCAGTTCAGTATGTTCGGCTT). Quantiﬁcation was per-
formed on a 7500 Fast (Applied Biosystems). PCR cycles proceeded as fol-
lows: initial denaturation for 30 s at 95 °C followed by 40 cycles at 95 °C
for 5 s and 60 °C for 30 s. At the end of the PCR, a melting curve analysis
was performed to show the speciﬁcity of the product detected. To calcu-
late the relative index of gene expression,weemployed the 2−ΔΔCtmeth-
od using untreated samples as a calibrator (Livak and Schmittgen, 2001).In vitro wound healing assay. To verify if lead induced cell migration, a
wound healing assay was performed. For this assay, cells were seeded
and cultured to conﬂuence in a 24-well plate. Then, the cells were
switched to serum-free medium for 24 h before the initiation of the ex-
periments. A wound was made with a P10 pipette tip (CRP, with a ﬁl-
ter). The medium was changed twice (5 mL/well) to wash away any
cell debris remaining in the wound area. A line was drawn through
the center of the wells, perpendicular to the wound. A picture was
taken at time zero at the site of intersection of the line and the wound.
Then, the cells were treated for 24 h with lead (20 μg/dL). At 24 h, we
took a picture in the same location. Adobe Photoshop CS2 was used toFig. 6. Effect of lead on vascular cyclooxygenase-2 (COX-2) expression and the relationship w
presence of Tempol (10 μM). Effect of lead on COX-2 (B) and COX-1 (C) protein expression. Rep
untreated cells (Ct), &P b 0.05 versus Pb using one-way ANOVA followed by Tukey test or Studdetermine the area of wound closure compared to time 0 for the stimu-
lus and with respect to the control situation.
Cell proliferation assay. Cell proliferation was assessed using a CellTiter
96 Non-Radioactive Cell Proliferation Assay (Promega Corporation,
Madison, WI, USA). VSMCs were seeded on 96-well plates (20 × 103
cells/well) in DMEM/F12 (HAM) medium and were allowed to attach
for 24–36 h. Afterwards, cells were switched to serum free medium
for 24-h. Cells were then treated with lead (20 μg/dL) or vehicle for
48 h. The proliferative response was quantiﬁed by adding MTS tetrazo-
lium solution (20 μL/well). After 2–3 h of incubation, absorbance was
measured at 490 nm in a microplate reader (ASYS Hitech GmbH,
Austria). Different assays were each performed in triplicate
Drugs and reagents. L-Phenylephrine hydrochloride, acetylcholine chlo-
ride, sodium nitroprusside, apocynin, lucigenin, mito-TEMPO, ML 171,
tempol (4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl), salts and
other reagents were purchased from Sigma Chemical Co. and Merck
(Darmstadt, Germany). DHE, streptomycin and penicillinwere obtained
from Invitrogen (Carlsbad, CA, USA). Celecoxib and rofecoxib were ob-
tained from Pﬁzer (New York, NY, USA) or LKT Laboratories (St. Paul,
Mn, USA), respectively. U0126 and SB203580 were obtained from
Calbiochem (Darmstadt, Germany). Lead acetate was obtained from
Vetec (Rio de Janeiro, RJ, Brazil). All drugs were dissolved in distilled
water except celecoxib, rofecoxib, U0126 and SB203580, which were
dissolved in DMSO. DMSO did not have any effect on the parameters
evaluated in VSMCs.
Data analysis and statistics. Contractile responses were expressed as a
percentage of the maximal response induced by 75mM KCl. Relaxationith oxidative stress. (A) Effects of lead (Pb) on COX-2 mRNA levels in the absence or the
resentative blots are also shown. Data are expressed as themean± SEM. *P b 0.05 versus
ent's t-test. Number of cell cultures is indicated in parentheses.
Fig. 8. Role of ERK1/2 and p38MAPK pathways on lead-induced NOX-1, NOX-4 and COX-2 expression. Effects of U0126 (10 μM) and SB203580 (10 μM) on lead (Pb)-induced (A) NOX-1,
(B)NOX-4 and (C)COX-2 gene expression in smoothmuscle cells. Data are expressed as themean±SEM. *Pb 0.05 versus untreated (Ct), &Pb 0.05 versus Pb byone-wayANOVA followed
by Tukey test. Number of cell cultures is indicated in parentheses.
Fig. 7. Lead induces ERK1/2 and p38MAPK phosphorylation. Effects of lead on (A) ERK1/2, (B) p38MAPK, (C) JNK and (D) Akt activation. Representative blots are also shown. The results
are expressed as the ratio between phospho-MAPK and totalMAPK and normalized to values obtained for unstimulated control (0) cells. Data are expressed as themean± SEM. *P b 0.05
versus unstimulated cells (0) by one-way ANOVA followed by Tukey test. Number of cell cultures is indicated in parentheses.
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ous contraction. For each concentration–response curve, the maximal
effect (Rmax) and the concentration of agonist that produced 50% of
the maximal response (EC50) were calculated using non-linear regres-
sion analysis (GraphPad Prism, GraphPad Software, Inc., San Diego,
CA). The sensitivities of the agonists were expressed as pD2 (− log
EC50). To compare the effects of endothelium denudation, L-NAME or
apocynin on the contractile responses to phenylephrine, some results
were expressed as differences in the area under the concentration re-
sponse curves (dAUC) for the control and experimental groups. AUCs
were calculated from the individual concentration–response plots
using a computer program (GraphPad Prism, GraphPad Software, Inc.,
San Diego, CA). The differences were expressed as the percentage of
the AUC of the corresponding control situation.
All values are expressed as the mean ± SEM of the number of ani-
mals or independent experiments in the case of cell cultures used in
each experiment. The results were analyzed using Student's t test or
one- or two-way ANOVA, followed by the Bonferroni post hoc test or
Tukey test by using GraphPad Prism Software. Differences were con-
sidered statistically signiﬁcant at P b 0.05.Results
Rats exposed to lead for 30 days had similar body weight [Control:
before 218±3.08 g and after 325±5.80 g (n=9); lead-treated: before
217 ± 2.57 g and after 328 ± 7.27 g (n = 9) P N 0.05] and tibia lengthFig. 9. Effects of lead on cellmigration and proliferation. Data are expressed as themean±
SEM. Number of cell cultures is indicated in parentheses.[Control: 3.8 ± 0.1 cm (n = 6); Lead-treated: 3.4 ± 0.1 cm (n = 9)
P N 0.05]. The left ventricular mass:tibia length ratio was not affected
in lead-treated animals (0.173 ± 0.003 g/cm) when compared with
controls (0.178 ± 0.006 g/cm). The blood lead concentration attained
was 21.7 ± 2.38 μg/dL (n = 6) and the systolic blood pressure (SBP)
was increased by treatment (Control: 127 ± 0.57 mmHg, n = 7; lead
treated: 144 ± 1.67 mm Hg, n = 7, P b 0.05).
Effects of lead treatment on vascular reactivity
Lead treatment did not affect the response to KCl (untreated: 3.75±
0.13 g, n = 9; lead-treated: 3.52 ± 0.19 g, n = 9; P N 0.05). However,
treatment increased vasoconstrictor responses to phenylephrine and
decreased the endothelium-dependent responses induced by ACh
(Figs. 1 A–B, Table 1). The vasodilator responses induced by SNP were
unaffected by lead treatment (Fig. 1 C). These results suggest that lead
treatment affects endothelial function in aortic rings.
Effects of lead treatment on endothelial modulation of
vasoconstrictor responses
To evaluate if lead treatment alters NOmodulation in aortic segment
responses, the effect of endothelium removal and incubation with the
NOS inhibitor L-NAME (100 μM) on vasoconstrictor responses were
investigated. Both endothelium removal and NOS inhibitor addition
left-shifted the concentration–response curves to phenylephrine in
aortic segments from both groups, but this effect was smaller in pre-
parations from lead-treated rats than in those from control rats, as
shown by the dAUC values (Figs. 2 A–B). These ﬁndings suggest that
NO production and/or bioavailability are reduced after lead treatment.
Role of oxidative stress and prostanoids on the effect of lead on
vasoconstrictor responses
Reduction in NO bioavailability caused by increased ROS production
is associated with endothelial dysfunction accompanying hypertension
(Cai and Harrison, 2000). The basal O2•− production in the aortas from
lead-treated rats was greater than that from the untreated rats (Fig. 3
A). The participation of ROS in the vascular responses was evaluated
using the NADPH oxidase inhibitor apocynin (30 μM). Apocynin re-
duced the vascular response to phenylephrine in both experimental
groups (Fig. 3 B, Table 1); however, this effect was greater in prepara-
tions from lead-treated rats than in those from control rats as demon-
strated by the dAUC (Fig. 3 B). gp91(phox), Cu/Zn-SOD and Mn-SOD
protein expression was increased in the aorta from the lead treated
group compared to controls (Fig. 3 C).
The cyclooxygenase inhibitor indomethacin (10 μM)was used to in-
vestigate the role of prostanoids on the increased response to phenyl-
ephrine in lead-treated rats. Indomethacin did not alter phenylephrine
responses in control aortic segments. However, in arteries from lead-
treated rats, indomethacin reduced phenylephrine contraction (Fig. 4
A, Table 1). We investigated COX-2 protein expression and observed
an increase in this enzyme in the lead-treated group (Fig. 4 B).
Altogether, these results show that chronic treatment with low con-
centrations of lead increases oxidative stress and prostanoid pathways
and could contribute to the impaired vascular function observed in
the aortas from lead-treated rats.
Effect of lead exposure on oxidative stress and COX-2 expression in VSMCs
In an attempt to investigate the underlying mechanism of lead ef-
fects on oxidation and COX-2 expression observed in vascular reactivity,
we used VSMCs. First, we evaluated cell viabilitywith 10, 20 and 100 μg/
dL lead acetate during 48 h using a MTT cell viability assay. No differ-
ences were observed in cell viability (data not shown). Therefore, we
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tration attained in blood from rats treated for 30 days with lead acetate.
Incubation of VSMCs with lead (20 μg/dL, 48 h) increased O2•− pro-
duction, as determined by increased DHE-induced ﬂuorescence
(Fig. 5A). This increased production of O2•− was diminished by the SOD
mimetic tempol and by the speciﬁc scavenger of mitochondrial super-
oxidemito-TEMPO (Fig. 5 A), suggesting a role for mitochondrial oxida-
tive stress in the effects of lead. Lead also increased NADPH oxidase
activity as well as the mRNA levels of the NADPH oxidase subunits
NOX-1 andNOX-4 (Figs. 5 B–D). The increased NADPH activitywas nor-
malized by ML 171 (0.5 μM) and tempol (10 μM). In addition, the
NADPH oxidase activity and NOX mRNA levels were reduced by the
COX-2 inhibitors celecoxib (10 μM) and rofecoxib (10 μM) (Figs. 5 B–
D), which implies a role for COX-2-derived products in NADPH oxidase
activation. We also studied whether lead-treatment might alter the
expression of the superoxide detoxiﬁcant enzyme SOD. Mn-SOD and
EC-SOD protein expression was augmented in VSMCs treated with
lead (Figs. 5 E and G). However, Cu/Zn-SOD protein expression was
not affected (Fig. 5 F).
VSMCs treated with lead for 48 h also increased COX-2 mRNA levels
(Fig. 6 A). This increase was accompanied by an increase in COX-2 pro-
tein expression, without changes in COX-1 protein expression (Figs. 6
B–C). In addition, we observed that pre-treatment of VSMCs with the
antioxidant tempol prevented lead-induced COX-2 gene expression,
suggesting a relationship between ROS and COX-2 products (Fig. 6 A).
MAPK signaling pathways involved in the lead-induced NOX and
COX-2 mRNA levels
The MAPK pathway plays a role in modulating COX-2 (expression
and activity) and ROS production (Ohnaka et al., 2000; Wang et al.,
2013). Thus, we investigated whether the MAPK signaling pathway
was involved in the effects induced by lead on NOX and COX-2 mRNA
levels. We observed a time-dependent stimulation of ERK1/2 by lead
at 30–60 min but not at long exposure times (3 and 24 h) (Fig. 7 A).
In contrast, p38 was activated by lead only after long exposure times
(24 h) (Fig. 7 B). However, neither JNK nor Akt was activated by lead
at any time points (Figs. 7 C–D). The p38 MAPK inhibitor SB203580
(10 μM) but not the ERK1/2MAPK inhibitor U0126 (10 μM) normalized
lead-induced NOX-1 gene expression (Fig. 8 A); both U0126 and
SB203580 normalized lead-induced NOX-4 and COX-2 gene expression
(Figs. 8 B–C). These ﬁndings suggest that the activation of these kinases
by lead is involved in events that induce NADPH oxidase and COX-2 ac-
tivation. However, lead did not induce either cell migration or prolifer-
ation (Figs. 9 A–B).
Discussion
The exposure to environmental chemicals, including lead, is emerg-
ing as a potential cardiovascular risk factor (Weinhold, 2004; Mamtani
et al., 2011; Simões et al., 2011). The main ﬁnding of the present study
is that 30-day treatment with a low dose of lead increases blood lead
concentrations to values (21.7 μg/dL) lower than the reference value
(60 μg/dL), but these concentrations are sufﬁcient to increase systolic
blood pressure and phenylephrine-induced contractility and to de-
crease endothelium-dependent vasodilator responses in rat aortas.
Our results also suggest that p38 and ERK1/2 MAPKs are involved in
the increase in vascular COX-2 levels and ROS production after lead
exposure that act in concert to produce the vascular changes that
could contribute to the occurrence of arterial hypertension.
The effects of lead on human health depend on blood levels and on
the duration of the exposure. Several studies have supported the associ-
ation between high blood lead levels and hypertension in humans
(Andrzejak et al., 2004; Patrick, 2006; Kosnett et al., 2007). The Agency
for Toxic Substances andDisease Registry (ATSDR) considered the refer-
ence blood lead concentration level to be 60 μg/dL (Patrick, 2006;Kosnett et al., 2007). Nevertheless, individuals with baseline blood
lead levels of 46.8 μg/dL or 67.8 μg/dL have also shown increases in ar-
terial pressure (Malvezzi et al., 2001; Andrzejak et al., 2004) suggesting
that even lower than recommended maximal doses might have cardio-
vascular deleterious consequences. A similar association was reported
in treated rats with lead blood concentrations between 31.8 μg/dL and
42.5 μg/dL (Gonick et al., 1997; Marques et al., 2001). Moreover, in the
present study, treated rats attained a blood lead concentration of
21.7 ± 2.38 μg/dL that increased systolic blood pressure.
The mechanisms by which lead may cause hypertension are not en-
tirely clear (Heydari et al., 2006). Different studies have identiﬁed sever-
al candidates, including oxidative stress, impairment of the NO system,
inﬂammation, dysregulation of vasoactive hormones, and alterations of
cellular Ca2+ transport and intracellular Ca2+ distribution (Goldstein,
1993; Feng et al., 1995; Heydari et al., 2006). Using animal models,
our group has already successfully documented that chronic exposure
to lead exerts detrimental effects on the function of the heart and
aorta (Simões et al., 2011; Fiorim et al., 2011; Silveira et al., 2014;
Fioresi et al., 2014). In the present study, aortic reactivity to phenyleph-
rinewas increased, whereas relaxation in response to acetylcholinewas
reduced. Similar ﬁndings were recently reported in aortas from rats
with blood lead levels smaller than those in the present study (Silveira
et al., 2014). Alterations in the reactivity of the aorta after lead treat-
ment were endothelium dependent, as evidenced by the magnitude of
lead-induced effects being reduced in aortic ringswithout endothelium.
In addition, the NOS inhibitor L-NAME increased the reactivity to phen-
ylephrine to a lower extent in arteries from lead-treated rats. These
results suggest that lead decreased endothelial NO bioavailability, con-
sequently increasing the reactivity to phenylephrine in aortic rings. In
agreement, a previous study showed that treatment with 100 ppm
lead acetate for 28 days reduces NO bioavailability in the rat aorta
(Karimi et al., 2002). However, our group has reported that low concen-
trations of lead increase theNObioavailability in the initial stages of lead
exposure (7 days) (Fiorim et al., 2011), but this effect might be changed
after a long exposure, aswe observed in the present study. However, the
endothelium-independent relaxation induced by the NO donor sodium
nitroprusside was not altered after 30 days of lead exposure, in agree-
ment with previous reports (Silveira et al., 2014).
Oxidative stress can lead to endothelial dysfunction, vascular struc-
tural alterations and hypertension, (Rodriguez-Iturbe et al., 2004;
Vaziri, 2004). The inactivation of NO by ROS can result in vasoconstric-
tion, increased platelet/leukocyte adhesion, vascular smooth muscle
cell migration/proliferation, and matrix accumulation leading to vascu-
lar remodeling (Touyz et al., 2011; Drummond et al., 2011). It is known
that increased ROS production contributes to the inﬂammatory process
associated with lead-induced hypertension (Vaziri et al., 1997; Silveira
et al., 2014). Herein, we observed increased superoxide anion produc-
tion in the aorta from lead-treated rats and in VSMCs exposed to lead.
In addition, the antioxidant apocynin reduced the vasoconstrictor re-
sponse induced by phenylephrine, more in aortas from lead-treated
rats, suggesting the involvement of superoxide anions in the vascular ef-
fects of lead, in accordance with the results recently described (Silveira
et al., 2014). On the other hand, the formedperoxynitrite by the reaction
of NOwith superoxide anionwould also contribute to the altered vascu-
lar responses observed after lead exposure, as it has been described by
other investigators in vascular diseases such as atherosclerosis, hyper-
tension, ischemia, endotoxic shock, and diabetes (Zou, 2007).
NADPH oxidase isoforms have been described as a major source of
ROS in vascular tissue (Griendling et al., 2000). Our results point to
the up-regulation of NADPH oxidase as the potential source of ROS in
lead-exposed vascular cells. Thus, we found that 1) the protein expres-
sion of the gp91(phox) NADPH oxidase subunit was increased in arter-
ies from treated rats; and 2) the mRNA levels of NOX-1 and NOX-4
subunits of NADPH oxidase and NADPH activity were increased in
lead-treated VSMCs. However, the participation of other sources of
ROS, such as themitochondria, cannot be discarded. Thus, the increased
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themitochondria-targeted SOD-2 mimetic mito-TEMPO. Decreased an-
tioxidant defenses would also contribute to the increased oxidative
stress. Amajor antioxidant defense system against O2•− are the superox-
ide dismutases which plays an important role in regulating blood pres-
sure and endothelial function by reducing extracellular O2•− level,
thereby preventing oxidative inactivation of NO released from endothe-
lium (Oury et al., 1994; Oury et al., 1996; Stralin et al., 1995). However,
the protein expression of Mn-SOD, Cu/Zn-SOD and EC-SOD was in-
creased in lead-treated arteries or VSMCs, suggesting that antioxidant
mechanisms are activated in lead-exposed cells probably to protect
against increased oxidative stress. In agreement, Ni et al. (2004) demon-
strated an increase in superoxide and hydrogen peroxide in human en-
dothelium and VSMCs from human coronary arteries after lead acetate
(1 ppm) treatment for 60 h, accompanied by an increase in Cu/Zn-
SOD protein expression. In the same study, the authors demonstrated
a signiﬁcant up-regulation of the gp91(phox) subunit of NADPHoxidase
in lead-exposed endothelial cells.
COX-2, the source of the prostaglandins that mediate inﬂammation,
is rapidly induced in response to different stimuli, including growth fac-
tors, proinﬂammatory cytokines and oxidative stress (Feng et al., 1995;
Martínez-Revelles et al., 2013; Wang et al., 2013). Increased vascular
COX-2 expression is usually associated with hypertension (Álvarez
et al., 2007). COX-2 derived prostanoidswere also implicated in the vas-
cular effects of lead (Silveira et al., 2014) and other heavy metals, such
as mercury (Pecanha et al., 2010). Herein, we observed an increase in
COX-2, but not in COX-1, protein or mRNA levels in aortas from lead-
treated rats and/or in VSMCs exposed to lead. After COX blockade
with indomethacin, a reduction in the phenylephrine-induced vasocon-
strictor responses in aortic segments from lead-treated rats was ob-
served, but not in control rats. These ﬁndings suggest the participation
of COX-2-derived prostanoids in the increased vasoconstrictor re-
sponses induced by lead treatment.
Some studies have reported that oxidative stress upregulates COX-2
expression (Feng et al., 1995; Garcia-Cohen et al., 2000; Álvarez et al.,
2007) and that antioxidant treatment reduces COX-2 expression (Feng
et al., 1995; Martínez-Revelles et al., 2013). In fact, increased ROS pro-
duction is hypothesized as one possible mechanism for the increased
vasomotor COX-2 activity in the setting of hypertension (Garcia-
Cohen et al., 2000; Álvarez et al., 2007; Martínez-Revelles et al., 2013).
As discussed above, we show that lead stimulated COX-2 expression
and ROS production. More importantly, our results also suggest an in-
teraction between COX-2 and ROS in VSMCs exposed to lead. Thus,
the ROS scavenger tempol reduced the increased COX-2 mRNA levels,
whereas the COX-2 inhibitors celecoxib and rofecoxib reduced the in-
creased NADPH activity and NOX-1 andNOX-4mRNA levels. This recip-
rocal interaction between both pathways would increase the harmful
effects of lead at the vascular level. In aortas from angiotensin II-
infused mice, the existence of a reciprocal relationship between ROS
and COX-2-derived products has been described as responsible for the
vascular dysfunction observed in this hypertension model (Martínez-
Revelles et al., 2013). Sancho et al. (2011) also showed a reciprocal reg-
ulation of NADPH oxidase and the COX-2 pathway in liver cells under
inﬂammatory conditions.
Previous reports indicate that MAPK pathways play an important
role inmodulating COX-2 (expression and activity) and ROS production
(Ohnaka et al., 2000;Wang et al., 2013). However, dissection of the spe-
ciﬁc molecular mechanisms and signaling cascades continues to be the
focus of intense research. Evidence shows that MAPK cascades are the
major signaling pathway that regulates cell proliferation,migration, dif-
ferentiation, inﬂammation and apoptosis (Yang et al., 2003). Moreover,
Aguado et al. (2013) reported that mercury, another heavy metal, in-
duced MAPK activation in VSMCs. Therefore, we speculated that
MAPK signaling pathways might be involved in the lead-induced alter-
ations in VSMCs. Our current data show that lead induces an early acti-
vation of ERK1/2 and a delayed activation of p38MAPKswithout effectson JNK. Posser et al. (2007) showed the toxic effect of lead on C6 glioma
cells and a signiﬁcant activation of p38 and JNK MAPKs. In addition, we
found that lead did not stimulate Akt phosphorylation, which corrobo-
rates results published by Lu et al. (2001) in human astrocytoma cells.
To investigate if the p38 and ERK1/2 MAPK pathways were involved
in COX-2 and NADPH oxidase activation, the effect of speciﬁc inhibitors
on COX-2, NOX-1 and NOX-4 expression was investigated. U0126 (in-
hibitor of ERK1/2) and SB203580 (inhibitor of p38) abrogated lead-
induced COX-2, NOX-1 and NOX-4 mRNA expression in cultured
VSMC. These ﬁndings suggest that the activation of inﬂammatory pro-
teins such as NADPH oxidase and COX-2 in response to lead exposure
is mediated through p38 and ERK1/2 signaling pathways. However,
when we analyzed the effects of lead on migration and proliferation in
VSMCs, no differences were observed in this model of exposure. There
is evidence that lead can increase the proliferation of rat liver cells
(Liu et al., 1997), VSMC (Fujiwara et al., 1995) and spleen cells
(Razani-Boroujerdi et al., 1999). Lu et al. (2001) demonstrated that
lead induces proliferation in human 1321N1 astrocytoma cells that is
mediated by the activation of the MEK1/2 and ERK1/2 signal transduc-
tion pathways in a PKC -dependent manner. The discrepancies with
our data could be due to differences in the exposure protocols related
to doses and/or duration of lead exposure.
In summary, the present study demonstrated for the ﬁrst time that
treatment with low doses of lead increased systolic arterial blood pres-
sure, promoted vascular dysfunction and activated MAPK signaling
pathways. These effects are associated with the activation of inﬂamma-
tory proteins such as NADPH oxidase and COX-2 that act in concert to
contribute to vascular dysfunction. These ﬁndings strongly support
that lead exposure should be considered an environmental risk factor
for cardiovascular disease.
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